Selinexor is marketed as XPOVIO, an oral nuclear export inhibitor used in specific relapsed/refractory multiple myeloma regimens and in relapsed/refractory diffuse large B-cell lymphoma after prior therapies. The DLBCL indication is under accelerated approval based on response rate pending confirmatory benefit. U.S. initial approval was in 2019.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07574528 |
A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07554482 |
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07479979 |
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma |
RECRUITING | PHASE1/PHASE2 |
| NCT07447817 |
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias |
NOT_YET_RECRUITING | PHASE2 |
| NCT07437170 |
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07215832 |
Karyopharm Expanded Access Program for Selinexor |
AVAILABLE | |
| NCT07204041 |
Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT07200102 |
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma |
RECRUITING | PHASE1 |
| NCT07172412 |
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07138209 |
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma |
RECRUITING | PHASE3 |
